DYAI - big biotech smell trade - high risk / high AROMA

7월 3일

Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

abcnews.go.com/Health/4th-human-case-bird-flu-linked-dairy-cow/story?id=111654647

4th human case of bird flu linked to dairy cow outbreak: CDC
The case was confirmed in a dairy worker in Colorado.

Great news recentley for the company:

Dyadic International, Inc. has struck a deal with Proliant Health and Biologicals to license its cutting-edge fungal production technology for manufacturing recombinant serum albumin. Dyadic stands to gain an initial $500,000, another half a million upon successful production strain transfer, and an additional $500,000 upon achieving a specified productivity level. Moreover, Dyadic will earn a share of the profits from Proliant’s sales of the animal-free product, marking a significant milestone in both companies’ commercial endeavors.

Watching Dyadic International; Zacks Small-Cap Research Gives Stock $9 Price Valuation

Dyadic Intl (NASDAQ: DYAI) and Proliant Health Biologicals to Launch $6 Billion Serum Albumin Market Product in 2025

Dyadic International And Proliant Health And Biologicals Announce Recombinant Albumin Development And Commercialization Partnership; Dyadic Will Receive An Upfront Milestone Payment Of 1.5M

Disclaimer

This content is for informational purposes only and should not be considered financial advice.